Holen Sie sich die Stockscreener-App
10.02
3.30%
0.32
Handel nachbörslich:
9.90
-0.12
-1.20%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CAPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$9.70
Offen:
$9.67
24-Stunden-Volumen:
1.26M
Relative Volume:
0.59
Marktkapitalisierung:
$634.88M
Einnahmen:
$27.10M
Nettoeinkommen (Verlust:
$-24.31M
KGV:
-12.07
EPS:
-0.83
Netto-Cashflow:
$-33.33M
1W Leistung:
-0.30%
1M Leistung:
-1.86%
6M Leistung:
-33.02%
1J Leistung:
+112.29%
1-Tages-Spanne:
$9.45
$10.10
1-Wochen-Bereich:
$9.45
$11.58
52-Wochen-Spanne:
$3.52
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Firmenname
Capricor Therapeutics Inc
Sektor
Branche
Telefon
(310) 358-3200
Adresse
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
Vergleichen Sie CAPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
10.02 | 634.88M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-20 | Eingeleitet | Roth Capital | Buy |
| 2024-10-21 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-17 | Eingeleitet | Oppenheimer | Outperform |
| 2024-01-05 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-10-26 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-12-26 | Herabstufung | Maxim Group | Buy → Hold |
| 2018-01-26 | Bestätigt | H.C. Wainwright | Buy |
| 2017-09-15 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-13 | Fortgesetzt | Rodman & Renshaw | Buy |
| 2016-07-06 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-06-15 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Capricor Therapeutics Inc Aktie (CAPR) Neueste Nachrichten
US FDA’s Top Cell and Gene Therapy Regulators Forced Out - insights.citeline.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor - Bluefield Daily Telegraph
Capricor gets FDA's Orphan Drug status for muscle disorder therapy - MSN
Capricor Therapeutics Announces Orphan Drug Designation for - GlobeNewswire
Capricor Therapeutics (CAPR) Rating Reiterated by Roth Capital | CAPR Stock News - GuruFocus
Capricor Therapeutics (CAPR) Gains FDA Orphan Drug Status for Deramiocel - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc.CAPR - PR Newswire
Capricor Therapeutics' Deramiocel Wins FDA Orphan Drug Designation for Becker Muscular Dystrophy - MarketScreener
Capricor Therapeutics (CAPR) Receives Orphan Drug Designation for BMD Treatment | CAPR Stock News - GuruFocus
Capricor Scores Double Win: FDA Orphan Drug Status for Becker MD Plus DMD Approval Progress - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor ... - Eagle-Tribune
FDA Grants Orphan Status to Capricor's Becker Muscular Dystrophy Treatment (CAPR) | CAPR Stock News - GuruFocus
Capricor Therapeutics (CAPR) Shares Dip Seen as Buying Opportuni - GuruFocus
Capricor Therapeutics (CAPR) Sees Unusual Put Activity | CAPR St - GuruFocus
Capricor (CAPR) Shares Decline Amid FDA Advisory Panel Developments | CAPR Stock News - GuruFocus
Capricor Therapeutics (CAPR) Receives Buy Rating from HC Wainwri - GuruFocus
Capricor Therapeutics (CAPR) Receives Buy Rating from HC Wainwright & Co. | CAPR Stock News - GuruFocus
Capricor Therapeutics (CAPR) Shares Drop After FDA Withdraws Mee - GuruFocus
Capricor gets Form 483 from FDA; WuXi Biologics’ new China factory - Endpoints News
Capricor says FDA inspection brought Form 483 with several observations - Yahoo Finance
Capricor Therapeutics (CAPR) Manufacturing Facility Cleared by F - GuruFocus
Capricor Therapeutics (CAPR) Shares Decline Amid FDA Inspection Report - GuruFocus
Capricor Therapeutics (CAPR) Advances Deramiocel Approval Proces - GuruFocus
Capricor: A Hold Rating With Regulatory FDA Form Given For Deramiocel Advancement (CAPR) - Seeking Alpha
Capricor Therapeutics Announces Key Regulatory Updates for its D - GuruFocus
FDA Completes Inspection of Capricor Therapeutics Manufacturing Facility For Deramiocel Approval: Retail Sees ‘Unimaginable Potential’ - Asianet Newsable
Capricor Therapeutics (CAPR) Manufacturing Facility Cleared by FDA | CAPR Stock News - GuruFocus
Capricor Therapeutics' Duchenne Therapy Facility Inspection Completed by FDA - MarketScreener
Capricor falls after facility inspection related to deramiocel - Seeking Alpha
Capricor Therapeutics stock falls after FDA inspection of manufacturing facility - Investing.com Australia
Capricor Therapeutics stock falls after FDA inspection of manufacturing facility By Investing.com - Investing.com Nigeria
Capricor’s DMD therapy clears FDA pre-license inspection By Investing.com - Investing.com Canada
Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program - GlobeNewswire
Capricor's DMD Drug Hits 3 Major FDA Milestones: Advisory Committee Set for July 30 - Stock Titan
Cantor Fitzgerald Estimates CAPR FY2026 Earnings - Defense World
Behind the Scenes of Capricor Therapeutics's Latest Options Trends - Benzinga
(CAPR) Trading Signals - news.stocktradersdaily.com
Wellington Management Group LLP Purchases New Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics Sees Unusually High Options Volume (NASDAQ:CAPR) - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor Therapeutics, Inc.CAPR - FinancialContent
Capricor Therapeutics (CAPR) Sees Borrow Rate Surge | CAPR Stock News - GuruFocus
Millennium Management LLC Acquires 12,285 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
BNP Paribas Financial Markets Reduces Stake in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Two Sigma Investments LP Has $1.64 Million Stake in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Bank of America Corp DE Purchases 154,127 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to Connect - ACCESS Newswire
Capricor Therapeutics Inc (NASDAQ:CAPR) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Deutsche Bank AG Takes Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to Reach Out - ACCESS Newswire
Finanzdaten der Capricor Therapeutics Inc-Aktie (CAPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Capricor Therapeutics Inc-Aktie (CAPR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Mar 03 '25 |
Option Exercise |
1.39 |
2,500 |
3,475 |
8,223 |
| Litvack Frank | Director |
Mar 03 '25 |
Option Exercise |
1.39 |
25,000 |
34,750 |
132,382 |
| DUNBAR GEORGE W JR | Director |
Mar 03 '25 |
Option Exercise |
1.39 |
750 |
1,042 |
11,306 |
| COLLIER EARL M JR | Director |
Feb 27 '25 |
Option Exercise |
1.39 |
750 |
1,042 |
57,606 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Dec 13 '24 |
Option Exercise |
1.39 |
8,000 |
11,120 |
28,047 |
| Litvack Frank | Director |
Dec 03 '24 |
Option Exercise |
1.10 |
20,391 |
22,430 |
46,278 |
| Nippon Shinyaku Co Ltd | 10% Owner |
Sep 20 '24 |
Buy |
5.36 |
2,798,507 |
14,999,998 |
7,090,351 |
| Musket David B | Director |
Aug 07 '24 |
Option Exercise |
1.39 |
34,000 |
47,260 |
81,692 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):